Wczytywanie spółki
Just reported
Q3 2026 results
From Orasure Technologies's results release of 9 listopada 2026; its quarterly report has since been filed.
Revenue
Actual
30,9M USD
+14% y/y
+0,9% q/qGuided
31M USD
midpoint
Within guide-0,3%EPS, GAAP
Actual
-0,19 USD
Guided
—
No guide given
Operating income, GAAP
Actual
-13M USD
Guided
—
No guide given
Company outlook
Q4 2026
- Revenue30M USD – 32M USD+16% y/y First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Orasure Technologies is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Instruments and Supplies
Graded A or B and worth $2B or more: A first, then the largest.
ISRGIntuitive Surgical, Inc.153,8B USDA+
MDLNMedline Inc.51,9B USDA
ALCAlcon Inc.36,1B USDA
BLCOBausch & Lomb Corp7,5B USDA-
ATRCAtriCure, Inc.2,9B USDA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 paź 2026CBGraded C, now B
MCKMckesson Corporation4 lis 2026BAGraded B, now A
CVSCVS Health Corp4 lis 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 lis 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 paź 2026CAGraded C, now A
Pełne sprawozdania finansowe →
Zbudowane z własnych raportów spółki Orasure Technologies, Inc. składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.
